A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis

References

• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct 22;388(10055):2023–2038.
   PubMed Web of Science ®Google Scholar
• Gibofsky A. Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsis. Am J Manag Care. 2014;20(7 Suppl):S128–35.
   PubMed Web of Science ®Google Scholar
• Nomen nescio. The global burden of rheumatoid arthritis will increase. Pharmaceutical Technology [Internet]. 2017 May 26. Available from: https://www.pharmaceutical-technology.com/research-reports/researchreportthe-global-burden-of-rheumatoid-arthritis-will-increase-5825875/.
   Google Scholar
• Van Onna M, Boonen A. The challenging interplay between rheumatoid arthritis, ageing and comorbidities. BMC Musculoskelet Disord. 2016;17(1). DOI:10.1186/s12891-016-1038-3
   PubMedGoogle Scholar
• National Rheumatoid Arthritis Society. The economic burden of rheumatoid arthritis. United Kingdom: National Rheumatoid Arthritis Society; 2010.
   Google Scholar
• Roubille C, Richer V, Starnino T, et al. Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the canadian dermatology-rheumatology comorbidity initiative. J Rheumatol. 2015 Oct;42(10):1767–1780.
   PubMed Web of Science ®Google Scholar
• Dougados M, van der Heijde D. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017 Jan;76(1):88–95.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Meroni M. Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis. J Inflamm Res. 2013;6:129.
   PubMedGoogle Scholar
• Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology. 2000;39(1):28–33.
   PubMed Web of Science ®Google Scholar
• Wasserman AM. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2011 Dec 1;84(11):1245–1252.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landew R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–975.
   PubMed Web of Science ®Google Scholar
• Luqmani R, Hennell S, Estrach C, et al. British society for rheumatology and british health professionals in rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford). 2009 Apr;48(4):436–439.
   PubMed Web of Science ®Google Scholar
• Einarsson JT, Willim M, Ernestam S, et al. Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a nationwide study in Sweden. Rheumatology (Oxford). 2019 Feb 1;58(2):227–236.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390(10093):457–468.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–662.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243–1252.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. 5th ed. Chichester: Wiley Online Library; 2008.
   Google Scholar
• Stevenson M, Archer R, Tosh J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess. 2016;20(35):1–610.
   Web of Science ®Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. 1st ed. Oxford: Oxford university press; 2006.
   Google Scholar
• Norton S, Sacker A, Dixey J, et al. Trajectories of functional limitation in early rheumatoid arthritis and their association with mortality. Rheumatology (Oxford). 2013;52(11):2016–2024.
   PubMed Web of Science ®Google Scholar
• Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. [ Review]. Health Technol Assess. 2011;15(14):1–278.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review (ICER). targeted immune modulators for rheumatoid arthritis: effectiveness & value, draft evidence report. 2017 [cited 2020 Jan]. Available from: https://icer-review.org/wp-content/uploads/2016/08/NECEPAC_RA_Draft_Report_012017.pdf
   Google Scholar
• Scholz S, Mittendorf T. Modeling rheumatoid arthritis using different techniques-a review of model construction and results. Health Econ Rev. 2014;4(1):1–16.
   PubMedGoogle Scholar
• Vij AS, Malaviya AN, Kumar S. Characteristics of rheumatoid arthritis patients at first presentation to a specialized rheumatology department. Int J Res Med Sci. 2015;3(8):2073.
   Google Scholar
• Caro J, Briggs AH, Siebert U, et al. ISPOR-SMDM modeling good research practices task force. Modeling good research practices - overview: a report of the ISPOR-SMDM modeling good practices task force-1. Value Health. 2012;15(6):796–803.
   PubMed Web of Science ®Google Scholar
• Karnon J, Stahl J, Brennan A, et al. Modeling using discrete event simulation: a report of the ISPOR-SMDM modeling good research practices task force-4. Value Health. 2012;15(6):821–827.
   Web of Science ®Google Scholar
• Eli L. Data on file: systematic literature review of clinical trials in rheumatoid arthritis. 2016.
   Google Scholar
• Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2. Value Health. 2011;14(4):429–437.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011;14(4):417–428.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; 2014.
   Google Scholar
• Carlson J, Ogale S, Dejonckheere F, et al. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis. Value Health. 2015;18(2):173–179.
   PubMed Web of Science ®Google Scholar
• Eli L. Data on file: patient HAQ trajectory beyond RA-BEAM study (RA-BEYOND). 2018.
   Google Scholar
• NICE. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. TA375. 2016 [cited 2020 Jan]. Available from: https://www.nice.org.uk/guidance/ta375/resources/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed-82602790920133
   Google Scholar
• Hernandez AM, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health. 2012;15(3):550–561.
   PubMed Web of Science ®Google Scholar
• Brennan A, Bansback N, Nixon R, et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British society for rheumatology biologics registry. Rheumatology. 2007;46(8):1345–1354.
   PubMed Web of Science ®Google Scholar
• Michaud K, Vera-Llonch M, Oster G. Mortality risk by functional status and health-related quality of life in patients with rheumatoid arthritis. J Rheumatol. 2012;39(1):54–59.
   PubMed Web of Science ®Google Scholar
• Wiles N, Cooper N, Symmons D. Resource use within the Norfolk Arthritis Register (NOAR) Cohort during the first five years of disease: report for Roche (NICE Data on File). London: NICE; 2005.
   Google Scholar
• Vemer P, Corro Ramos I, van Voorn GAK, et al. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. PharmacoEconomics. 2015;34:349–361.
   Web of Science ®Google Scholar
• Alemao E, Al MJ, Boonen AA, et al. Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLoS One. 2018;13(10):e0205013.
   PubMed Web of Science ®Google Scholar
• Wailoo A, Hock ES, Stevenson M, et al. The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2017;21(71):1–258.
   PubMed Web of Science ®Google Scholar
• Vermeer M, Kievit W, Kuper HH, et al. Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry. BMC Musculoskelet Disord. 2013;14:350.
   PubMed Web of Science ®Google Scholar
• van den Hout WB, Goekoop-Ruiterman YP, Allaart CF, et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2009;61(3):291–299.
   PubMedGoogle Scholar
• van de Laar CJ, Oude Voshaar MAH, Vonkeman HE. Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry. BMC Rheumatol. 2019;3:16.
   PubMedGoogle Scholar
• van de Laar C, Voshaar MO, Fakhouri W, et al. OP0313 Cost-effectiveness of a JAK1/JAK2-Inhibitor vs. a biologic disease-modifying antirheumatic drug in a treat-to-target strategy for rheumatoid arthritis. BMJ Ann Rheumatic Dis. 2019;78(2):238–239.
   Google Scholar